Andreas Trojan

Hirslanden Klinik Im Park
Zuerich (kreis 7) / Hirslanden, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.

Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.

Journal: Cancers

Published: January 27, 2026

Using Machine Learning Approaches on Dynamic Patient-Reported Outcomes to Cluster Cancer Treatment-Related Symptoms.

Using Machine Learning Approaches on Dynamic Patient-Reported Outcomes to Cluster Cancer Treatment-Related Symptoms.

Journal: Current oncology (Toronto, Ont.)

Published: April 06, 2025

Unsupervised Dynamic Electronic Patient-Reported Outcome Reporting of Immunotherapy-Related Symptoms in Cancer Patients.

Unsupervised Dynamic Electronic Patient-Reported Outcome Reporting of Immunotherapy-Related Symptoms in Cancer Patients.

Journal: Oncology

Published: March 07, 2025

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer.

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: February 15, 2025

Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learning.

Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learning.

Journal: Frontiers in digital health

Published: June 04, 2024

Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data.

Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data.

Journal: JMIR formative research

Published: December 29, 2023

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.

Journal: JMIR cancer

Published: November 01, 2023

Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.

Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.

Journal: Case reports in oncology

Published: October 16, 2023

Interference of Herbal Medicine with Axitinib in Metastatic Renal Cell Cancer Treatment: A Case Study.

Interference of Herbal Medicine with Axitinib in Metastatic Renal Cell Cancer Treatment: A Case Study.

Journal: Case reports in oncology

Published: September 24, 2023

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

Journal: Journal of geriatric oncology

Published: February 02, 2022

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.

Journal: Endocrine oncology (Bristol, England)

Published: January 23, 2022

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.

Journal: Scientific reports

Published: June 04, 2021

Showing 1-12 of 43

Last Updated: 09/26/2026